Latest Onyx Pharmaceuticals (ONXX) Headlines Ma
Post# of 4
Posted On: 03/13/2014 12:41:06 AM
Latest Onyx Pharmaceuticals (ONXX) Headlines
MacroGenics Appoints Matthew Fust to Its Board of Directors
GlobeNewswire - Thu Mar 06, 6:09AM CST
MacroGenics, Inc. (Nasdaq:MGNX) today announced that its Board of Directors is increasing its size from seven to eight members and that Matthew Fust has been appointed to fill the vacancy. Mr. Fust joins the Board and becomes Chairman of its Audit Committee, effective immediately. Mr. Fust will serve as a Class II Director, with Class II having a term expiring at the annual meeting of stockholders to be held in 2015.
Autologous Tissue Repair to 2018. Products, Indications, Markets and Forecasts
PR Newswire - Fri Feb 14, 12:00PM CST
Dublin - Research and Markets (http://www.researchandmarkets.com/research/n7sxmf/autologous_tissue) has announced the addition of the "Autologous Tissue Repair to 2018. Products, Indications, Markets and Forecasts" report to their offering.
Silverpop Launches 2014 Digital Marketing Roadshow Aimed at Helping Marketers Navigate the Customer-Driven World
PR Newswire - Wed Feb 12, 8:20AM CST
Silverpop(TM), a leading provider of digital marketing software that enables personalized customer experiences, today announces the 2014 launch of Digital Marketing University. The series is a global, multi-city educational roadshow aimed at helping marketers of all types thrive in today's ever changing, customer-driven landscape. Silverpop thought leaders and experts from several Silverpop technology and consulting partners will lead discussions to guide marketers along their pursuit to provide customers with a unified, multichannel experience.
Ligand to Receive $1 Million Kyprolis(R) Commercial Milestone Payment from Onyx Pharmaceuticals
Business Wire - Mon Feb 10, 3:15PM CST
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it has earned $1 million commercial milestone payment from Onyx Pharmaceuticals (a subsidiary of Amgen, Inc.). The milestone payment was triggered by the achievement of over $250 million of annual product sales of Kyprolis in 2013. Ligand will recognize the $1 million payment in the first quarter of 2014, consistent with the Company's revenue recognition policy. Ligand receives royalties for Kyprolis and is eligible to receive additional commercial and regulatory milestones.
Ultragenyx Appoints Clay Siegall, Ph.D. and Matthew Fust to Board of Directors
GlobeNewswire - Thu Feb 06, 8:00AM CST
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the appointment of Clay B. Siegall, Ph.D. and Matthew Fust to the company's Board of Directors effective January 30, 2014. Dr. Siegall, currently President, Chief Executive Officer and Chairman of the Board of Seattle Genetics, Inc., and Mr. Fust, formerly Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals, Inc. will serve as independent directors for Ultragenyx. With these additions, Ultragenyx extends gratitude and appreciation for the counsel provided by Mr. Ben Auspitz, who has resigned from his position on the Board effective January 30, 2014.
PPL Corporation to Conduct Webcast on 2013 Fourth-Quarter and Year-End Results, Provide 2014 Earnings Guidance
PR Newswire - Wed Jan 29, 8:16AM CST
PPL Corporation (NYSE: PPL) will release consolidated fourth-quarter and year-end 2013 earnings results, and issue 2014 earnings guidance, before the stock market opens on Thursday, Feb. 6.
Amgen 4Q profit leaps 30 percent on higher sales
By LINDA A. JOHNSON - AP - Tue Jan 28, 6:27PM CST
Amgen Inc.'s fourth-quarter profit jumped 30 percent mainly due to a tax benefit from prior-year audits, an acquisition and higher sales for nearly all its drugs — much of it from price hikes.
Amgen's 2013 Revenues Increased 8 Percent To $18.7 Billion And Adjusted Earnings Per Share (EPS) Increased 17 Percent To $7.60
PR Newswire - Tue Jan 28, 3:02PM CST
Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2013. Key results include:
Military Spokesman - Unfreezing Us Aid to Egypt Will Be Positive Step
All Africa Global Media - Thu Jan 16, 10:54AM CST
Military Spokesman Ahmed Mohamed Ali expressed content that a decision will be made by the United States to resume economic aid to Egypt. Ali said that "unfreezing the aid is a positive step."
Monarques Intersects a 66 Metre Gold Zone on the Simkar Property
Marketwire - Thu Jan 16, 8:09AM CST
MONARQUES RESOURCES INC. ("Monarques" or the "Corporation") (TSX VENTURE: MQR)(FRANKFURT: MR7) is pleased to report on the initial results of the latest drilling on the Simkar gold property (the "Property"), in which it acquired a 50% interest under an agreement signed with Eloro Resources Ltd. on September 23, 2013. The Property is located in the heart of the Val-d'Or mining camp, just north of the Cadillac-Larder Lake Break, in the Abitibi Greenstone Belt.
Dundee Industrial REIT December 2013 Monthly Distribution
Marketwire - Wed Dec 18, 11:15AM CST
DUNDEE INDUSTRIAL REIT (TSX: DIR.UN) today announced its December 2013 monthly distribution in the amount of 5.833 cents per Unit (70 cents annualized). The December distribution will be payable on January 15, 2014 to unitholders of record as at December 31, 2013.
Amgen To Host Post American Society of Hematology (ASH) Summary Webcast
PR Newswire - Tue Dec 10, 1:46PM CST
Amgen (NASDAQ:AMGN) and its subsidiary Onyx Pharmaceuticals, Inc. today announced that they will hold a post American Society of Hematology (ASH) summary webcast on Wednesday, Dec. 11, 2013, at 11 a.m. PST. Pablo Cagnoni, M.D., president of Onyx Pharmaceuticals, Inc. and Anthony C. Hooper, executive vice president of Global Commercial Operations at Amgen, will participate in the call to discuss a brief summary of data presented at ASH. In addition, they will discuss a summary of feedback received from key opinion leaders and the steps Amgen is taking to develop Kyprolis® (carfilzomib) across all lines of therapy to address unmet needs in multiple myeloma patients.
The International Myeloma Foundation Announces Partnership With Onyx Pharmaceuticals to Support Black Swan Research Initiative(TM)
Marketwire - Fri Dec 06, 7:30AM CST
The International Myeloma Foundation (IMF) -- improving the quality of life of myeloma patients while working toward prevention and a cure -- and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (NASDAQ: AMGN), today announced the start of a multi-year collaboration in support of the IMF's Black Swan Research Initiative(R) (BSRI(R)). The BSRI is led by a multinational consortium of leading myeloma experts who are studying and harnessing new technologies and treatments with the goal of developing a cure for myeloma.
Research Reports: Kidney Cancer - Pipeline Review, H2 2013
M2 - Wed Nov 27, 2:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/jnwbgg/kidney_cancer) has announced the addition of the "Kidney Cancer - Pipeline Review, H2 2013" report to their offering. 'Kidney Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Kidney Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Kidney Cancer. Scope - A snapshot of the global therapeutic scenario for Kidney Cancer. - A review of the Kidney Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Kidney Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Kidney Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Kidney Cancer pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Amgen Inc. Amorfix Life Sciences Ltd. Astellas Pharma Inc. Onyx Pharmaceuticals, Inc. Patrys Limited Dendreon Corporation Green Cross Corporation Rexahn Pharmaceuticals, Inc. Antisense Pharma GmbH Chipscreen Biosciences Ltd CIMAB S.A. Aurigene Discovery Technologies Limited Alethia Biotherapeutics Inc. GenSpera, Inc. Cerulean Pharma, Inc. Gene Signal International SA. Neotropix, Inc. Deciphera Pharmaceuticals, LLC MSM Protein Technologies, Inc. Vascular Biogenics Ltd. Pharminox Limited Esperance Pharmaceuticals, Inc. Welichem Biotech Inc. Cellceutix Corporation TRACON Pharmaceuticals, Inc. Advanced Cancer Therapeutics RECEPTA Biopharma S.A. Mediolanum farmaceutici S.p.A. FCB-Pharmicell Co.,Ltd. For more information visit http://www.researchandmarkets.com/research/jn...ney_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Here's What SAC Capital Has Been Buying and Selling
Nicole Seghetti, The Motley Fool - Motley Fool - Mon Nov 25, 6:03PM CST
Money managers must disclose what stocks they've bought and sold every quarter via 13F filings. Their latest moves can shine a bright light on smart stock picks. Today, let's look at SAC Capital Advisors. Earlier this year, many investors became...
Inflammatory Bowel Disease - Pipeline Review, H2 2013
M2 - Tue Nov 19, 3:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/g29c7q/inflammatory) has announced the addition of the "Inflammatory Bowel Disease - Pipeline Review, H2 2013" report to their offering. 'Inflammatory Bowel Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Inflammatory Bowel Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease. Scope - A snapshot of the global therapeutic scenario for Inflammatory Bowel Disease. - A review of the Inflammatory Bowel Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Inflammatory Bowel Disease pipeline on the basis of route of administration and molecule type. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Inflammatory Bowel Disease. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Inflammatory Bowel Disease pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Key Topics Covered: Introduction Inflammatory Bowel Disease Overview Therapeutics Development Companies Involved in Inflammatory Bowel Disease Therapeutics Development Inflammatory Bowel Disease - Therapeutics Assessment Drug Profiles Appendix Companies Mentioned - 4SC - AlbireoPharma - Addex Pharmaceuticals - Basilea Pharmaceutica - Biotec Pharmacon - Compugen - Emergent BioSolutions - Eisai - Ferring Pharmaceuticals - GlaxoSmithKline - Indus Biotech Private Limited - Inotek Pharmaceuticals - Jenrin Discovery - Johnson & Johnson - KYORIN Pharmaceutical - Karo Bio - Lycera - Morria Biopharmaceuticals - Mitsubishi Tanabe Pharma - N30 Pharmaceuticals - Nephrx Corporation - Ono Pharmaceutical - Onyx Pharmaceuticals - PepTcell Limited - Paratek Pharmaceuticals - RaQualia Pharma - Rigel Pharmaceuticals - Santarus, Inc. - Synergy Pharmaceuticals - TiGenix NV - Upsher-Smith Laboratories - VentiRx Pharmaceuticals - Ventria Bioscience - Vitae Pharmaceuticals - Zealand Pharma A/S - iCo Therapeutics For more information visit http://www.researchandmarkets.com/research/g2...flammatory
Researchers Receive Grants From NCCN Oncology Research Program Funded Through Onyx Pharmaceuticals
Marketwire - Mon Nov 11, 12:26PM CST
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) recently awarded four research grants to investigators following NCCN ORP Scientific Review Committee analysis of proposals submitted in response to the NCCN Carfilzomib and Oprozomib Request for Proposals (RFP). These grants were made possible through a grant from Onyx Pharmaceuticals, Inc., an Amgen subsidiary, to scientifically evaluate and define clinical effectiveness of carfilzomib and oprozomib in non-Hodgkin lymphomas.
Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
PR Newswire - Thu Nov 07, 3:38PM CST
Amgen (NASDAQ:AMGN) and its subsidiary Onyx Pharmaceuticals, Inc. today announced that nearly 40 company-sponsored and investigator-sponsored investigational studies evaluating carfilzomib, a second-generation proteasome inhibitor, and oprozomib, an oral second-generation proteasome inhibitor in early development, will be presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition on December 7-10, 2013 at the Ernest N. Morial Convention Center in New Orleans, LA.
T-Cell Lymphomas Drug Pipeline Report - H2 2013 Review
M2 - Thu Nov 07, 8:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/whxwtv/tcell_lymphomas) has announced the addition of the "T-Cell Lymphomas - Pipeline Review, H2 2013" report to their offering. 'T-Cell Lymphomas - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for T-Cell Lymphomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for T-Cell Lymphomas. Scope - A snapshot of the global therapeutic scenario for T-Cell Lymphomas. - A review of the T-Cell Lymphomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the T-Cell Lymphomas pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned - Bristol-Myers Squibb Company - Kyowa Hakko Kirin Co., Ltd. - Seattle Genetics, Inc. - Emergent BioSolutions Inc. - Infinity Pharmaceuticals, Inc. - Nippon Kayaku Co., Ltd. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Mundipharma International Limited - Pharmacyclics, Inc. - Chipscreen Biosciences Ltd - Acetylon Pharmaceuticals, Inc. - PharmaMar, S.A. For more information visit http://www.researchandmarkets.com/research/wh..._lymphomas
Cutaneous T-Cell Lymphoma Drug Pipeline Report, H2 2013 Review
M2 - Wed Nov 06, 10:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/n6q727/cutaneous_tcell) has announced the addition of the "Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2013" report to their offering. 'Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma. Scope - A snapshot of the global therapeutic scenario for Cutaneous T-Cell Lymphoma. - A review of the Cutaneous T-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cutaneous T-Cell Lymphoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned - Johnson & Johnson - Kyowa Hakko Kirin Co., Ltd. - Seattle Genetics, Inc. - Emergent BioSolutions Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Eisai Co., Ltd. - Galderma S.A. - Onyx Pharmaceuticals, Inc. - Mundipharma International Limited - Innate Pharma SA - Spectrum Pharmaceuticals, Inc. - Chipscreen Biosciences Ltd - Mondobiotech Holding AG - Yaupon Therapeutics, Inc. - ELORAC, Inc. For more information visit http://www.researchandmarkets.com/research/n6...eous_tcell
MacroGenics Appoints Matthew Fust to Its Board of Directors
GlobeNewswire - Thu Mar 06, 6:09AM CST
MacroGenics, Inc. (Nasdaq:MGNX) today announced that its Board of Directors is increasing its size from seven to eight members and that Matthew Fust has been appointed to fill the vacancy. Mr. Fust joins the Board and becomes Chairman of its Audit Committee, effective immediately. Mr. Fust will serve as a Class II Director, with Class II having a term expiring at the annual meeting of stockholders to be held in 2015.
Autologous Tissue Repair to 2018. Products, Indications, Markets and Forecasts
PR Newswire - Fri Feb 14, 12:00PM CST
Dublin - Research and Markets (http://www.researchandmarkets.com/research/n7sxmf/autologous_tissue) has announced the addition of the "Autologous Tissue Repair to 2018. Products, Indications, Markets and Forecasts" report to their offering.
Silverpop Launches 2014 Digital Marketing Roadshow Aimed at Helping Marketers Navigate the Customer-Driven World
PR Newswire - Wed Feb 12, 8:20AM CST
Silverpop(TM), a leading provider of digital marketing software that enables personalized customer experiences, today announces the 2014 launch of Digital Marketing University. The series is a global, multi-city educational roadshow aimed at helping marketers of all types thrive in today's ever changing, customer-driven landscape. Silverpop thought leaders and experts from several Silverpop technology and consulting partners will lead discussions to guide marketers along their pursuit to provide customers with a unified, multichannel experience.
Ligand to Receive $1 Million Kyprolis(R) Commercial Milestone Payment from Onyx Pharmaceuticals
Business Wire - Mon Feb 10, 3:15PM CST
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it has earned $1 million commercial milestone payment from Onyx Pharmaceuticals (a subsidiary of Amgen, Inc.). The milestone payment was triggered by the achievement of over $250 million of annual product sales of Kyprolis in 2013. Ligand will recognize the $1 million payment in the first quarter of 2014, consistent with the Company's revenue recognition policy. Ligand receives royalties for Kyprolis and is eligible to receive additional commercial and regulatory milestones.
Ultragenyx Appoints Clay Siegall, Ph.D. and Matthew Fust to Board of Directors
GlobeNewswire - Thu Feb 06, 8:00AM CST
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the appointment of Clay B. Siegall, Ph.D. and Matthew Fust to the company's Board of Directors effective January 30, 2014. Dr. Siegall, currently President, Chief Executive Officer and Chairman of the Board of Seattle Genetics, Inc., and Mr. Fust, formerly Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals, Inc. will serve as independent directors for Ultragenyx. With these additions, Ultragenyx extends gratitude and appreciation for the counsel provided by Mr. Ben Auspitz, who has resigned from his position on the Board effective January 30, 2014.
PPL Corporation to Conduct Webcast on 2013 Fourth-Quarter and Year-End Results, Provide 2014 Earnings Guidance
PR Newswire - Wed Jan 29, 8:16AM CST
PPL Corporation (NYSE: PPL) will release consolidated fourth-quarter and year-end 2013 earnings results, and issue 2014 earnings guidance, before the stock market opens on Thursday, Feb. 6.
Amgen 4Q profit leaps 30 percent on higher sales
By LINDA A. JOHNSON - AP - Tue Jan 28, 6:27PM CST
Amgen Inc.'s fourth-quarter profit jumped 30 percent mainly due to a tax benefit from prior-year audits, an acquisition and higher sales for nearly all its drugs — much of it from price hikes.
Amgen's 2013 Revenues Increased 8 Percent To $18.7 Billion And Adjusted Earnings Per Share (EPS) Increased 17 Percent To $7.60
PR Newswire - Tue Jan 28, 3:02PM CST
Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2013. Key results include:
Military Spokesman - Unfreezing Us Aid to Egypt Will Be Positive Step
All Africa Global Media - Thu Jan 16, 10:54AM CST
Military Spokesman Ahmed Mohamed Ali expressed content that a decision will be made by the United States to resume economic aid to Egypt. Ali said that "unfreezing the aid is a positive step."
Monarques Intersects a 66 Metre Gold Zone on the Simkar Property
Marketwire - Thu Jan 16, 8:09AM CST
MONARQUES RESOURCES INC. ("Monarques" or the "Corporation") (TSX VENTURE: MQR)(FRANKFURT: MR7) is pleased to report on the initial results of the latest drilling on the Simkar gold property (the "Property"), in which it acquired a 50% interest under an agreement signed with Eloro Resources Ltd. on September 23, 2013. The Property is located in the heart of the Val-d'Or mining camp, just north of the Cadillac-Larder Lake Break, in the Abitibi Greenstone Belt.
Dundee Industrial REIT December 2013 Monthly Distribution
Marketwire - Wed Dec 18, 11:15AM CST
DUNDEE INDUSTRIAL REIT (TSX: DIR.UN) today announced its December 2013 monthly distribution in the amount of 5.833 cents per Unit (70 cents annualized). The December distribution will be payable on January 15, 2014 to unitholders of record as at December 31, 2013.
Amgen To Host Post American Society of Hematology (ASH) Summary Webcast
PR Newswire - Tue Dec 10, 1:46PM CST
Amgen (NASDAQ:AMGN) and its subsidiary Onyx Pharmaceuticals, Inc. today announced that they will hold a post American Society of Hematology (ASH) summary webcast on Wednesday, Dec. 11, 2013, at 11 a.m. PST. Pablo Cagnoni, M.D., president of Onyx Pharmaceuticals, Inc. and Anthony C. Hooper, executive vice president of Global Commercial Operations at Amgen, will participate in the call to discuss a brief summary of data presented at ASH. In addition, they will discuss a summary of feedback received from key opinion leaders and the steps Amgen is taking to develop Kyprolis® (carfilzomib) across all lines of therapy to address unmet needs in multiple myeloma patients.
The International Myeloma Foundation Announces Partnership With Onyx Pharmaceuticals to Support Black Swan Research Initiative(TM)
Marketwire - Fri Dec 06, 7:30AM CST
The International Myeloma Foundation (IMF) -- improving the quality of life of myeloma patients while working toward prevention and a cure -- and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (NASDAQ: AMGN), today announced the start of a multi-year collaboration in support of the IMF's Black Swan Research Initiative(R) (BSRI(R)). The BSRI is led by a multinational consortium of leading myeloma experts who are studying and harnessing new technologies and treatments with the goal of developing a cure for myeloma.
Research Reports: Kidney Cancer - Pipeline Review, H2 2013
M2 - Wed Nov 27, 2:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/jnwbgg/kidney_cancer) has announced the addition of the "Kidney Cancer - Pipeline Review, H2 2013" report to their offering. 'Kidney Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Kidney Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Kidney Cancer. Scope - A snapshot of the global therapeutic scenario for Kidney Cancer. - A review of the Kidney Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Kidney Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Kidney Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Kidney Cancer pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Amgen Inc. Amorfix Life Sciences Ltd. Astellas Pharma Inc. Onyx Pharmaceuticals, Inc. Patrys Limited Dendreon Corporation Green Cross Corporation Rexahn Pharmaceuticals, Inc. Antisense Pharma GmbH Chipscreen Biosciences Ltd CIMAB S.A. Aurigene Discovery Technologies Limited Alethia Biotherapeutics Inc. GenSpera, Inc. Cerulean Pharma, Inc. Gene Signal International SA. Neotropix, Inc. Deciphera Pharmaceuticals, LLC MSM Protein Technologies, Inc. Vascular Biogenics Ltd. Pharminox Limited Esperance Pharmaceuticals, Inc. Welichem Biotech Inc. Cellceutix Corporation TRACON Pharmaceuticals, Inc. Advanced Cancer Therapeutics RECEPTA Biopharma S.A. Mediolanum farmaceutici S.p.A. FCB-Pharmicell Co.,Ltd. For more information visit http://www.researchandmarkets.com/research/jn...ney_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Here's What SAC Capital Has Been Buying and Selling
Nicole Seghetti, The Motley Fool - Motley Fool - Mon Nov 25, 6:03PM CST
Money managers must disclose what stocks they've bought and sold every quarter via 13F filings. Their latest moves can shine a bright light on smart stock picks. Today, let's look at SAC Capital Advisors. Earlier this year, many investors became...
Inflammatory Bowel Disease - Pipeline Review, H2 2013
M2 - Tue Nov 19, 3:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/g29c7q/inflammatory) has announced the addition of the "Inflammatory Bowel Disease - Pipeline Review, H2 2013" report to their offering. 'Inflammatory Bowel Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Inflammatory Bowel Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease. Scope - A snapshot of the global therapeutic scenario for Inflammatory Bowel Disease. - A review of the Inflammatory Bowel Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Inflammatory Bowel Disease pipeline on the basis of route of administration and molecule type. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Inflammatory Bowel Disease. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Inflammatory Bowel Disease pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Key Topics Covered: Introduction Inflammatory Bowel Disease Overview Therapeutics Development Companies Involved in Inflammatory Bowel Disease Therapeutics Development Inflammatory Bowel Disease - Therapeutics Assessment Drug Profiles Appendix Companies Mentioned - 4SC - AlbireoPharma - Addex Pharmaceuticals - Basilea Pharmaceutica - Biotec Pharmacon - Compugen - Emergent BioSolutions - Eisai - Ferring Pharmaceuticals - GlaxoSmithKline - Indus Biotech Private Limited - Inotek Pharmaceuticals - Jenrin Discovery - Johnson & Johnson - KYORIN Pharmaceutical - Karo Bio - Lycera - Morria Biopharmaceuticals - Mitsubishi Tanabe Pharma - N30 Pharmaceuticals - Nephrx Corporation - Ono Pharmaceutical - Onyx Pharmaceuticals - PepTcell Limited - Paratek Pharmaceuticals - RaQualia Pharma - Rigel Pharmaceuticals - Santarus, Inc. - Synergy Pharmaceuticals - TiGenix NV - Upsher-Smith Laboratories - VentiRx Pharmaceuticals - Ventria Bioscience - Vitae Pharmaceuticals - Zealand Pharma A/S - iCo Therapeutics For more information visit http://www.researchandmarkets.com/research/g2...flammatory
Researchers Receive Grants From NCCN Oncology Research Program Funded Through Onyx Pharmaceuticals
Marketwire - Mon Nov 11, 12:26PM CST
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) recently awarded four research grants to investigators following NCCN ORP Scientific Review Committee analysis of proposals submitted in response to the NCCN Carfilzomib and Oprozomib Request for Proposals (RFP). These grants were made possible through a grant from Onyx Pharmaceuticals, Inc., an Amgen subsidiary, to scientifically evaluate and define clinical effectiveness of carfilzomib and oprozomib in non-Hodgkin lymphomas.
Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
PR Newswire - Thu Nov 07, 3:38PM CST
Amgen (NASDAQ:AMGN) and its subsidiary Onyx Pharmaceuticals, Inc. today announced that nearly 40 company-sponsored and investigator-sponsored investigational studies evaluating carfilzomib, a second-generation proteasome inhibitor, and oprozomib, an oral second-generation proteasome inhibitor in early development, will be presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition on December 7-10, 2013 at the Ernest N. Morial Convention Center in New Orleans, LA.
T-Cell Lymphomas Drug Pipeline Report - H2 2013 Review
M2 - Thu Nov 07, 8:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/whxwtv/tcell_lymphomas) has announced the addition of the "T-Cell Lymphomas - Pipeline Review, H2 2013" report to their offering. 'T-Cell Lymphomas - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for T-Cell Lymphomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for T-Cell Lymphomas. Scope - A snapshot of the global therapeutic scenario for T-Cell Lymphomas. - A review of the T-Cell Lymphomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the T-Cell Lymphomas pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned - Bristol-Myers Squibb Company - Kyowa Hakko Kirin Co., Ltd. - Seattle Genetics, Inc. - Emergent BioSolutions Inc. - Infinity Pharmaceuticals, Inc. - Nippon Kayaku Co., Ltd. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Mundipharma International Limited - Pharmacyclics, Inc. - Chipscreen Biosciences Ltd - Acetylon Pharmaceuticals, Inc. - PharmaMar, S.A. For more information visit http://www.researchandmarkets.com/research/wh..._lymphomas
Cutaneous T-Cell Lymphoma Drug Pipeline Report, H2 2013 Review
M2 - Wed Nov 06, 10:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/n6q727/cutaneous_tcell) has announced the addition of the "Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2013" report to their offering. 'Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma. Scope - A snapshot of the global therapeutic scenario for Cutaneous T-Cell Lymphoma. - A review of the Cutaneous T-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cutaneous T-Cell Lymphoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned - Johnson & Johnson - Kyowa Hakko Kirin Co., Ltd. - Seattle Genetics, Inc. - Emergent BioSolutions Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Eisai Co., Ltd. - Galderma S.A. - Onyx Pharmaceuticals, Inc. - Mundipharma International Limited - Innate Pharma SA - Spectrum Pharmaceuticals, Inc. - Chipscreen Biosciences Ltd - Mondobiotech Holding AG - Yaupon Therapeutics, Inc. - ELORAC, Inc. For more information visit http://www.researchandmarkets.com/research/n6...eous_tcell
(0)
(0)Onyx Service & Solutions, Inc. (OSRV) Stock Research Links
Scroll down for more posts ▼